Duoneb and Rivaroxaban drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Duoneb (albuterol sulfate; ipratropium bromide) and Rivaroxaban (rivaroxaban). Common drug interactions include perirectal abscess among females and adenocarcinoma pancreas among males.

The phase IV clinical study analyzes what interactions people have when they take Duoneb and Rivaroxaban. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Duoneb?

Duoneb has active ingredients of albuterol sulfate; ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 8,093 Duoneb users. Check the latest studies of Duoneb.

What is Rivaroxaban?

Rivaroxaban has active ingredients of rivaroxaban. It is often used in blood clots. eHealthMe is studying from 26,544 Rivaroxaban users. Check the latest studies of Rivaroxaban.



On Jul, 19, 2026

16 people who take Duoneb and Rivaroxaban together, and have interactions are studied.

Duoneb and Rivaroxaban drug interactions.

What are the common drug interactions of Duoneb and Rivaroxaban, by gender? *:

female:

  1. Perirectal abscess
  2. Subcutaneous abscess
  3. Plasma cell myeloma (cancer that begins in plasma cells)
  4. Abdominal pain
  5. Anaemia (lack of blood)
  6. Anal abscess
  7. Blood lactate dehydrogenase increased
  8. Blood pressure decreased
  9. Cough
  10. Drug ineffective

male:

  1. Adenocarcinoma pancreas (cancer of pancreas)
  2. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  3. Atrial flutter (an abnormal heart rhythm that occurs in the atria of the heart)
  4. Respiratory syncytial virus infection (viral disease of respiratory system)
  5. Eosinophilic pneumonia acute (eosinophil accumulates in the lung-acute)
  6. Pneumonitis (inflammation of the walls of the alveoli in the lungs)

What are the common drug interactions of Duoneb and Rivaroxaban, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Abdominal pain
  2. Anaemia (lack of blood)
  3. Blood lactate dehydrogenase increased
  4. Cough
  5. Haptoglobin decreased
  6. Headache (pain in head)
  7. Reticulocyte count increased
  8. Sepsis (a severe blood infection that can lead to organ failure and death)
  9. Vomiting

50-59:

  1. Abscess limb (limb infection)
  2. Cellulitis (infection under the skin)
  3. Perirectal abscess
  4. Subcutaneous abscess
  5. Anal abscess
  6. Drug ineffective
  7. Genital abscess (build up of pus in genital)
  8. Liver injury
  9. Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath)
  10. Necrotising fasciitis (an uncommon life-threatening soft-tissue infection)

60+:

  1. Adenocarcinoma pancreas (cancer of pancreas)
  2. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  3. Haemoglobin decreased
  4. Muscular weakness (muscle weakness)
  5. Pneumonitis (inflammation of the walls of the alveoli in the lungs)
  6. Unresponsive to stimuli
  7. Atrial flutter (an abnormal heart rhythm that occurs in the atria of the heart)
  8. Painful defaecation
  9. Plasma cell myeloma (cancer that begins in plasma cells)
  10. Respiratory syncytial virus infection (viral disease of respiratory system)

What are the existing conditions these people have? *

  1. Pain: 5 people, 31.25%
  2. Dyspnea (difficult or laboured breathing): 4 people, 25.00%
  3. Itching: 3 people, 18.75%
  4. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 18.75%
  5. Constipation: 3 people, 18.75%
  6. Multiple Myeloma (cancer of the plasma cells): 3 people, 18.75%
  7. Type 2 Diabetes: 2 people, 12.50%
  8. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 12.50%
  9. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 12.50%
  10. Escherichia Infection (bacterial infection by escherichia coli): 2 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Duoneb and Rivaroxaban?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Duoneb and Rivaroxaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Duoneb:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Rivaroxaban:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Duoneb and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rivaroxaban and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on albuterol sulfate; ipratropium bromide and rivaroxaban (the active ingredients of Duoneb and Rivaroxaban, respectively), and Duoneb and Rivaroxaban (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: